AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23622912 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate CKD (30-59 mL/min)
Number of subjects: 942
Study 23622912 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe CKD (<30 mL/min)
Number of subjects: 942
Study 23622912 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Hemodialysis (HD)
Number of subjects: 942
Study 21839455 — intervention group
Group type: EXPERIMENTAL
Intervention: LFHCC n‐3 diet (low-fat high-carbohydrate diet supplemented with 1.24g/day of long‐chain n‐3 polyunsaturated fatty acids)
Number of subjects: 337
Study 21839455 — intervention group
Group type: COMPARATOR
Intervention: HSFA diet (high saturated fat diet)
Number of subjects: 337
Study 21839455 — intervention group
Group type: COMPARATOR
Intervention: HMUFA diet (high monounsaturated fat diet)
Number of subjects: 337
Study 21839455 — intervention group
Group type: COMPARATOR
Intervention: LFHCC diet (low-fat high-carbohydrate diet with placebo)
Number of subjects: 337
Study 19339808 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollen group (received grass pollen, grass and olive pollen, or hazel, alder and birch pollen according to a 3-week titration cluster)
Number of subjects: 157
Study 19339808 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM group (received HDM extract according to a 2-week titration cluster)
Number of subjects: 157
Study 17038230 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-based antibiotics
Number of subjects: 60
Study 17038230 — intervention group
Group type: COMPARATOR
Intervention: Empiric amoxicillin-clavulanate (40 mg/kg/day)
Number of subjects: 60
Study 15053895 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunologic therapies (specifics not provided)
Number of subjects: 0
Study 15053895 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin (single dose)
Number of subjects: 0
Study 15053895 — intervention group
Group type: EXPERIMENTAL
Intervention: DPT-1 parenteral trials (insulin administration)
Number of subjects: 0
Study 15053895 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer assays (tetramers, enzyme-linked immunospot assays)
Number of subjects: 0
Study 10757146 — intervention group
Group type: EXPERIMENTAL
Intervention: Small dose instruction
Number of subjects: 130
Study 10757146 — intervention group
Group type: EXPERIMENTAL
Intervention: Large dose instruction
Number of subjects: 130
Study 10757146 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer
Number of subjects: 130
Study 10757146 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed drinks
Number of subjects: 130
Study 10757146 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight liquor
Number of subjects: 130
Study 10757146 — intervention group
Group type: EXPERIMENTAL
Intervention: Wine
Number of subjects: 130
Study 9089564 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg E2V for 11 days, followed by 2 mg E2V + 10 mg MPA for 10 days and placebo for 7 days
Number of subjects: 78
Study 9089564 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg E2V for 70 days, 2 mg E2V + 20 mg MPA for 14 days, and placebo for 7 days
Number of subjects: 78
Study 9089564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 8385230 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard methadone services (SMS) - same dose of methadone plus counseling
Number of subjects: 92
Study 8385230 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced methadone services (EMS) - same dose of methadone plus counseling and on-site medical/psychiatric, employment, and family therapy
Number of subjects: 92
Study 8385230 — intervention group
Group type: COMPARATOR
Intervention: Minimum methadone services (MMS) - methadone alone (a minimum of 60 mg/d) with no other services
Number of subjects: 92
Study 3544605 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin-dihydroergotamine once a day
Number of subjects: 200
Study 3544605 — intervention group
Group type: COMPARATOR
Intervention: Heparin-dihydroergotamine twice a day
Number of subjects: 200
Study 3544605 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 29644504 — intervention group
Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 1242
Study 29644504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever smokers
Number of subjects: 1242
Study 27403059 — intervention group
Group type: EXPERIMENTAL
Intervention: Carie-care (chemomechanical caries removal) in clinical setting
Number of subjects: 80
Study 27403059 — intervention group
Group type: COMPARATOR
Intervention: Smart Burs (mechanical caries removal) in clinical setting
Number of subjects: 80
Study 27403059 — intervention group
Group type: EXPERIMENTAL
Intervention: Carie-care (chemomechanical caries removal) in community setting
Number of subjects: 80
Study 27403059 — intervention group
Group type: COMPARATOR
Intervention: Atraumatic restorative technique (ART) in community setting
Number of subjects: 80
Study 25385173 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan and atorvastatin (ARB)
Number of subjects: 41
Study 25385173 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril and atorvastatin (ACEI)
Number of subjects: 41
Study 25385173 — intervention group
Group type: COMPARATOR
Intervention: CAD group
Number of subjects: 41
Study 25385173 — intervention group
Group type: COMPARATOR
Intervention: non-CAD group
Number of subjects: 41
Study 23523162 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype + Phenotype model
Number of subjects: 2415
Study 23523162 — intervention group
Group type: COMPARATOR
Intervention: Phenotype model
Number of subjects: 2415
Study 23523162 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status and ARMS2 genotype
Number of subjects: 2415
Study 21701080 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral EGD
Number of subjects: 25
Study 21701080 — intervention group
Group type: COMPARATOR
Intervention: Transnasal EGD
Number of subjects: 25
Study 19623684 — intervention group
Group type: COMPARATOR
Intervention: Dietary measures and treadmill training at 60% HRmax (G2)
Number of subjects: 0
Study 19623684 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary measures, treadmill training at 60% HRmax, and strength training (G3)
Number of subjects: 0
Study 19623684 — intervention group
Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 0
Study 16682738 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cisplatin and fluorouracil (reference arm in Western trials)
Number of subjects: 2600
Study 16682738 — intervention group
Group type: COMPARATOR
Intervention: Single-agent fluorouracil or S-1 (used in Japanese trials)
Number of subjects: 2600
Study 16682738 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet regimens (used in Western studies)
Number of subjects: 2600
Study 16682738 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer regimens (upcoming in Europe and Asia)
Number of subjects: 2600
Study 15450636 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-assisted (PA) intervention
Number of subjects: 583
Study 15450636 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 583
Study 15450636 — intervention group
Group type: EXPERIMENTAL
Intervention: Woman-only (WO)
Number of subjects: 583
Study 11171710 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based home-care program (HCP)
Number of subjects: 122
Study 11171710 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical care (Control)
Number of subjects: 122
Study 9312453 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane, nitrous oxide, and ondansetron (Group O)
Number of subjects: 300
Study 9312453 — intervention group
Group type: COMPARATOR
Intervention: Propofol and nitrous oxide (Group P)
Number of subjects: 300
Study 9312453 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study 9312453 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based anaesthesia
Number of subjects: 300
Study 7584301 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced infants (10-month-olds)
Number of subjects: 51
Study 7584301 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with experiences at both 10 months and 14 months
Number of subjects: 51
Study 7584301 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with a single 14-month experience
Number of subjects: 51
Study 7584301 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined experience groups (from Studies 1 and 2)
Number of subjects: 51
Study 7584301 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced children
Number of subjects: 51
Study 2572911 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonography
Number of subjects: 52
Study 2572911 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography
Number of subjects: 52
Study 2572911 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 52
Study 950374 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.1 IU/kg BW) administered at various times (0400 h, 0800 h, 1200 h, 1600 h, 2000 h, 2400 h)
Number of subjects: 4
Study 31589074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia/Hyperoxia Training (IHHT)
Number of subjects: 55
Study 31589074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia/Normoxia Training (IHT)
Number of subjects: 55
Study 31589074 — intervention group
Group type: COMPARATOR
Intervention: Sham control (placebo)
Number of subjects: 55
Study 28343696 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ hypothermic perfusion with retrograde outflow
Number of subjects: 18
Study 28343696 — intervention group
Group type: COMPARATOR
Intervention: Intermittent vascular inflow occlusion
Number of subjects: 18
Study 26121460 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus regimen with glargine once daily and glulisine before meals (n = 66)
Number of subjects: 134
Study 26121460 — intervention group
Group type: COMPARATOR
Intervention: NPH twice daily and regular insulin before meals (n = 68)
Number of subjects: 134
Study 26121460 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus regimen with glargine/glulisine
Number of subjects: 134
Study 26121460 — intervention group
Group type: COMPARATOR
Intervention: NPH/regular regimen
Number of subjects: 134
Study 24739235 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 40) with access to a nurse-managed telephone support line and colorectal cancer screening website
Number of subjects: 2395
Study 24739235 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 39) with standard clinical screening practice
Number of subjects: 2395
Study 24739235 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients whose physician promoted the FOBT
Number of subjects: 2395
Study 24739235 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who reported having done an FOBT in the past
Number of subjects: 2395
Study 24739235 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 50-59 years
Number of subjects: 2395
Study 24739235 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients completing the test
Number of subjects: 2395
Study 22180596 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood perceptions (neighborhood problems and neighborhood vigilance)
Number of subjects: 384
Study 20683380 — intervention group
Group type: EXPERIMENTAL
Intervention: ranibizumab (0.3 mg)
Number of subjects: 0
Study 20683380 — intervention group
Group type: EXPERIMENTAL
Intervention: ranibizumab (0.5 mg)
Number of subjects: 0
Study 20683380 — intervention group
Group type: COMPARATOR
Intervention: Control (photodynamic therapy)
Number of subjects: 0
Study 20683380 — intervention group
Group type: COMPARATOR
Intervention: Control (sham)
Number of subjects: 0
Study 18618933 — intervention group
Group type: EXPERIMENTAL
Intervention: ACOG recommendations
Number of subjects: 90
Study 18618933 — intervention group
Group type: COMPARATOR
Intervention: Randomized clinical trials (RCTs)
Number of subjects: 90
Study 16191910 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health program including parent education, toothbrushing instruction, and fluoride tablets (0.25 mg/day)
Number of subjects: 804
Study 16191910 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health program
Number of subjects: 804
Study 14639093 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 115
Study 10655292 — intervention group
Group type: EXPERIMENTAL
Intervention: Medi-Jector administration of ganirelix (2 mg s.c. once daily for 7 days)
Number of subjects: 16
Study 10655292 — intervention group
Group type: COMPARATOR
Intervention: Conventional needle injection of ganirelix (2 mg s.c. once daily for 7 days)
Number of subjects: 16
Study 9547443 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril
Number of subjects: 30
Study 9547443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8290683 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (≤ 6 mg)
Number of subjects: 54
Study 8290683 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine (≤ 90 mg)
Number of subjects: 54
Study 8290683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 2961039 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination analgesic/muscle relaxant
Number of subjects: 0
Study 2961039 — intervention group
Group type: COMPARATOR
Intervention: Components of the combination therapy
Number of subjects: 0
Study 2961039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30588067 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Pressure Release (MPR)
Number of subjects: 45
Study 30588067 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique (MET)
Number of subjects: 45
Study 30588067 — intervention group
Group type: COMPARATOR
Intervention: Control condition (postural advice and at-home neck exercises)
Number of subjects: 45
Study 27742577 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oral morphine
Number of subjects: 185
Study 27742577 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 185
Study 24452727 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 3491
Study 22905819 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending to the action
Number of subjects: 0
Study 22905819 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending to the object
Number of subjects: 0
Study 22905819 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent action-object clips
Number of subjects: 0
Study 22905819 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruency in different tasks
Number of subjects: 0
Study 21122603 — intervention group
Group type: EXPERIMENTAL
Intervention: First-trimester ultrasound screening for Down syndrome (DS)
Number of subjects: 2026
Study 21122603 — intervention group
Group type: COMPARATOR
Intervention: Routine ultrasound examination in the second trimester
Number of subjects: 2026
Study 18775429 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Hp therapy plus iron (amoxicillin, clarithromycin, and omeprazole + 90-day oral ferrous sulfate)
Number of subjects: 200
Study 18775429 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron alone (90-day oral iron)
Number of subjects: 200
Study 18775429 — intervention group
Group type: COMPARATOR
Intervention: Anti-Hp therapy alone (2-week anti-Hp therapy)
Number of subjects: 200
Study 18775429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 18775429 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Hp therapy plus iron
Number of subjects: 200
Study 18775429 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron alone
Number of subjects: 200
Study 18775429 — intervention group
Group type: COMPARATOR
Intervention: Anti-Hp therapy alone
Number of subjects: 200
Study 16394323 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg) with piperine (5 mg)
Number of subjects: 20
Study 16394323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12891198 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg/day)
Number of subjects: 181
Study 12891198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 12891198 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 181
Study 10552188 — intervention group
Group type: EXPERIMENTAL
Intervention: tedisamil 100 mg b.i.d.
Number of subjects: 48
Study 10552188 — intervention group
Group type: COMPARATOR
Intervention: atenolol 50 mg b.i.d.
Number of subjects: 48
Study 8911832 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (0.3 g.kg‐1 body mass)
Number of subjects: 7
Study 8911832 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CaCO3)
Number of subjects: 7
Study 8388090 — intervention group
Group type: EXPERIMENTAL
Intervention: IV cyclophosphamide/ACTH with outpatient IV cyclophosphamide boosters (700 mg/m2 every other month for 2 years)
Number of subjects: 256
Study 8388090 — intervention group
Group type: COMPARATOR
Intervention: IV cyclophosphamide/ACTH without outpatient IV cyclophosphamide boosters
Number of subjects: 256
Study 8388090 — intervention group
Group type: EXPERIMENTAL
Intervention: IV cyclophosphamide/ACTH with outpatient IV cyclophosphamide boosters
Number of subjects: 256
Study 3725002 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (100 mg) + Ethanol (0.5 ml/kg)
Number of subjects: 6
Study 3725002 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (50 mg) + Ethanol (0.5 ml/kg)
Number of subjects: 6
Study 3725002 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0.5 ml/kg) alone
Number of subjects: 6
Study 3725002 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Ethanol (0.5 ml/kg)
Number of subjects: 6
Study 3725002 — intervention group
Group type: COMPARATOR
Intervention: Trazodone (100 mg) alone
Number of subjects: 6
Study 3725002 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (50 mg) alone
Number of subjects: 6
Study 31662331 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of lapatinib and trastuzumab
Number of subjects: 97
Study 31662331 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks of lapatinib and trastuzumab
Number of subjects: 97
Study 31662331 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of lapatinib and trastuzumab in ER-positive subgroup
Number of subjects: 97
Study 31662331 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks of lapatinib and trastuzumab in ER-positive subgroup
Number of subjects: 97
Study 29503102 — intervention group
Group type: EXPERIMENTAL
Intervention: Training session using voices different from those in the experimental session but of the same voice category
Number of subjects: 0
Study 29503102 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 0
Study 27906936 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-nalbuphine (LN) group
Number of subjects: 106
Study 27906936 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (L) group
Number of subjects: 106
Study 25518506 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinitrosyl iron complex (1.5 or 3 mg/kg)
Number of subjects: 30
Study 22507264 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy (suryanamaskara, asanas, pranayama, and meditation) for 1 hour per day for 12 weeks
Number of subjects: 90
Study 22507264 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical exercises
Number of subjects: 90
Study 22507264 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy
Number of subjects: 90
Study 20442215 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline chest radiograph (CXR) followed by three annual single-view CXRs.
Number of subjects: 77464
Study 18544464 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management program for smoking cessation combining pharmacotherapy, telephone counseling, and physician feedback, repeated intervention over two years.
Number of subjects: 750
Study 18544464 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management program for smoking cessation
Number of subjects: 750
Study 16402744 — intervention group
Group type: EXPERIMENTAL
Intervention: Reality monitoring
Number of subjects: 0
Study 16402744 — intervention group
Group type: COMPARATOR
Intervention: External source monitoring
Number of subjects: 0
Study 12504838 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 alone
Number of subjects: 13
Study 12504838 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 combined with BQ-788
Number of subjects: 13
Study 12504838 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 alone and combined with BQ-788
Number of subjects: 13
Study 10397414 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 39
Study 10397414 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 39
Study 10397414 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic patients and family history positive parents
Number of subjects: 39
Study 10397414 — intervention group
Group type: COMPARATOR
Intervention: Family history negative parents and normal subjects
Number of subjects: 39
Study 10397414 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of illness, neuroleptic medication, and negative symptoms
Number of subjects: 39
Study 10180853 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling intervention
Number of subjects: 1
Study 1812479 — intervention group
Group type: EXPERIMENTAL
Intervention: Euphylong
Number of subjects: 17
Study 1812479 — intervention group
Group type: COMPARATOR
Intervention: Reference drug
Number of subjects: 17
Study 6980622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 263
Study 6980622 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 263
Study 6980622 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-SMX
Number of subjects: 263
Study 30531478 — intervention group
Group type: COMPARATOR
Intervention: Cebranopadol 200 μg
Number of subjects: 42
Study 30531478 — intervention group
Group type: COMPARATOR
Intervention: Cebranopadol 400 μg
Number of subjects: 42
Study 30531478 — intervention group
Group type: EXPERIMENTAL
Intervention: Cebranopadol 800 μg
Number of subjects: 42
Study 30531478 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 8 mg
Number of subjects: 42
Study 30531478 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 16 mg
Number of subjects: 42
Study 30531478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42